Benitec Biopharma Inc
BNTC
Company Profile
Business description
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Contact
3940 Trust Way
HaywardCA94545
USAT: +1 510 780-0819
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
19
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
stocks
Morningstar's verdict on SpaceX
Mark and Shani run through the business and what our analysts think about the IPO.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 10.70 | 0.12% |
| CAC 40 | 8,388.84 | 48.13 | 0.58% |
| DAX 40 | 24,697.01 | 196.57 | -0.79% |
| Dow JONES (US) | 51,979.97 | 313.13 | 0.61% |
| FTSE 100 | 10,460.84 | 31.99 | 0.31% |
| HKSE | 23,412.18 | 75.90 | 0.33% |
| NASDAQ | 25,785.34 | 198.30 | 0.78% |
| Nikkei 225 | 69,174.97 | 613.41 | -0.88% |
| NZX 50 Index | 13,400.66 | 35.11 | -0.26% |
| S&P 500 | 7,412.99 | 47.53 | 0.65% |
| S&P/ASX 200 | 8,808.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,110.81 | 4.56 | 0.11% |